AbbVie Deutschland GmbH & Co. KG

• A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 as monotherapy and in combination with bevacizum… Recruiting
  2023-509335-60-00 Phase I 4 countries
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting
  2023-505277-32-00 Phase III 16 countries CYCLOPHOSPHAMIDE; DOXORUBICIN HYDROCHLORIDE; EPCORITAMAB; PREDNISONE; RITUXIMAB;…
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting
  2023-505749-14-00 Phase III 16 countries TELISOTUZUMAB VEDOTIN
• Evaluation of the Pharmacokinetics and Safety of Upadacitinib in Pediatric Subjects with Polyarticular Course Juvenile Idiopathic Arthritis … Recruiting
  2023-505060-11-00 Phase I (Other) 5 countries UPADACITINIB
• A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants with Multiple Myeloma Receiving Etentamig (ABBV-… Recruiting
  2024-515770-27-00 Phase I/II 1 country ETENTAMIG
• Mass Balance Study of [14C] ABBV-932 in Healthy Male Volunteers Recruiting
  2024-514454-75-00 Phase I (Other) 1 country
• A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination with Atezolizumab… Recruiting
  2024-517490-24-00 Phase II 5 countries HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST SEZ6, CONJUGATED TO (2S)-2-(2-BROMOAC…
• A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab ( Switch-Up ) Recruiting
  2025-523347-35-00 Phase III/IV 3 countries UPADACITINIB
• A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratum… Recruiting
  2025-520897-21-00 Phase II/III 3 countries ETENTAMIG
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad… Recruiting
  2025-521124-29-00 Phase II/III 9 countries TELISOTUZUMAB ADIZUTECAN
• A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Intravenous Mirvetuximab Soravtansin… Recruiting
  2025-521606-18-00 Phase II 5 countries MIRVETUXIMAB SORAVTANSINE
• Study to Assess the Injection Burden, Safety, Efficacy, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) … Recruiting
  2024-512298-28-00 Phase III/IV 13 countries RANIBIZUMAB; SURABGENE LOMPARVOVEC
• A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Fluorouracil, … Recruiting
  2024-513008-32-00 Phase II 3 countries BUDIGALIMAB; FLUOROURACIL; OXALIPLATIN; TELISOTUZUMAB ADIZUTECAN
• A study to investigate the safety and efficacy of MEDI0618 compared to placebo in adult participants with episodic migraine Recruiting
  2024-512904-21-00 Phase II 8 countries MEDI0618
• A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antim… Recruiting
  2024-517140-65-00 Phase I/II 7 countries SURZETOCLAX
• A study to evaluate dosing schedules of mirvetuximab soravtansine in patients with epithelial ovarian, primary peritoneal, or fallopian tube… Recruiting
  2024-517184-23-00 Phase II 4 countries MIRVETUXIMAB SORAVTANSINE; PREDNISOLONE ACETATE
• A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutec… Recruiting
  2024-518015-19-00 Phase II 4 countries TELISOTUZUMAB ADIZUTECAN
• A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Compared to Oral Lenvatinib Capsul… Recruiting
  2024-518012-39-00 Phase I 1 country
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination with Osimertinib as Firs… Recruiting
  2024-518586-10-00 Phase II/III 4 countries TELISOTUZUMAB ADIZUTECAN
• A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic… Recruiting
  2024-516772-15-00 Phase I 2 countries
• A Phase 1/2 Study of Etentamig in Combination with a CELMoD Agent for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma Recruiting
  2024-512146-41-00 Phase I/II 3 countries ETENTAMIG; IBERDOMIDE
• A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis Recruiting
  2024-519291-11-00 Phase II 4 countries LUTIKIZUMAB; RISANKIZUMAB
• A Study to Assess the Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Telisotuzumab Adizutecan in Part… Recruiting
  2024-512981-33-00 Phase II 6 countries TELISOTUZUMAB ADIZUTECAN
• A Study to Assess the Adverse Events and Change in Disease Activity of Atogepant Oral Tablets in Pediatric Participants with Chronic Migrain… Recruiting
  2024-513836-28-00 Phase III 6 countries ATOGEPANT

Showing 25–48 of 138 trials